Trial Profile
A multi-center, randomized, double-blind, dose-escalation safety study of MP4CO in clinically stable adult sickle cell patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jun 2016
Price :
$35
*
At a glance
- Drugs MP4CO (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Sponsors Sangart
- 27 Mar 2014 New trial record